anastrozole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
aromatase inhibitors, imidazole-triazole derivatives 210 120511-73-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • anastrozole
  • anastrazole
  • anastrol
  • arimidex
A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.
  • Molecular weight: 293.37
  • Formula: C17H19N5
  • CLOGP: 1.75
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 78.29
  • ALOGS: -3.65
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.06 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.632 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.824 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 93.541 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.979 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 49.880 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 73.180 % High 1
herg hERG pIC50 4.616 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.346 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 4.699 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 57.200 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK 38
kinase-selectivity-class BRAF,EIF2AK3,PDK1 3
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.782 High 1
mh-clint Mouse hepatocyte intrinsic clearance 6.124 High 1
mppb Mouse plasma protein binding (% unbound) 47.010 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 7.727 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 66.820 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.639 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 81.040 % High 1
rppb Rat plasma protein binding (% unbound) 47.580 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 312.608 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 27, 1995 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 1399.65 11.63 566 64142 24939 90538800
Malignant neoplasm progression 1073.79 11.63 763 63945 106107 90457632
Metastases to liver 729.43 11.63 373 64335 28434 90535305
Metastases to lung 640.72 11.63 284 64424 15707 90548032
Neutropenia 515.82 11.63 715 63993 224189 90339550
Hot flush 502.64 11.63 383 64325 59105 90504634
Breast cancer recurrent 400.43 11.63 150 64558 5353 90558386
Neoplasm progression 381.43 11.63 289 64419 44197 90519542
Osteonecrosis 378.45 11.63 235 64473 26006 90537733
Bone pain 359.90 11.63 321 64387 61662 90502077
Breast cancer metastatic 357.22 11.63 187 64521 14945 90548794
White blood cell count decreased 357.20 11.63 514 64194 166595 90397144
Disease progression 338.04 11.63 484 64224 156131 90407608
Osteonecrosis of jaw 330.74 11.63 252 64456 38851 90524888
Breast cancer 309.28 11.63 277 64431 53484 90510255
Metastases to lymph nodes 294.73 11.63 151 64557 11538 90552201
Maternal exposure during pregnancy 232.88 11.63 5 64703 360058 90203681
Tumour marker increased 225.71 11.63 101 64607 5706 90558033
Systemic lupus erythematosus 216.35 11.63 10 64698 361886 90201853
Ejection fraction decreased 214.97 11.63 166 64542 26087 90537652
Contraindicated product administered 208.79 11.63 4 64704 320135 90243604
Infusion related reaction 206.35 11.63 27 64681 416753 90146986
Synovitis 197.46 11.63 9 64699 329743 90233996
Drug ineffective 193.83 11.63 441 64267 1383857 89179882
Metastases to spine 167.85 11.63 72 64636 3671 90560068
Tooth extraction 165.69 11.63 103 64605 11410 90552329
Fatigue 160.71 11.63 1385 63323 1152638 89411101
Carbohydrate antigen 15-3 increased 158.10 11.63 58 64650 1949 90561790
Glossodynia 154.15 11.63 23 64685 321756 90241983
Pericarditis 153.55 11.63 10 64698 270141 90293598
Neuropathy peripheral 152.79 11.63 316 64392 136654 90427085
Joint swelling 152.40 11.63 85 64623 503215 90060524
Second primary malignancy 152.27 11.63 94 64614 10284 90553455
Metastasis 148.13 11.63 77 64631 6060 90557679
Arthralgia 146.43 11.63 1003 63705 777519 89786220
Leukopenia 146.36 11.63 260 64448 100450 90463289
Bone lesion 144.67 11.63 77 64631 6360 90557379
Human rhinovirus test positive 142.48 11.63 44 64664 859 90562880
Respiratory syncytial virus test positive 139.69 11.63 45 64663 1013 90562726
Therapeutic product effect decreased 139.69 11.63 17 64691 277554 90286185
Pseudocirrhosis 132.24 11.63 42 64666 902 90562837
Wound 129.32 11.63 29 64679 302951 90260788
Folliculitis 127.68 11.63 4 64704 204349 90359390
Treatment failure 124.01 11.63 32 64676 303896 90259843
Irritable bowel syndrome 123.04 11.63 6 64702 207442 90356297
Psoriatic arthropathy 119.90 11.63 12 64696 228323 90335416
Rheumatoid arthritis 117.48 11.63 56 64652 362558 90201181
Myalgia 111.75 11.63 326 64382 174799 90388940
Muscle injury 105.10 11.63 5 64703 176649 90387090
Viral test positive 104.28 11.63 32 64676 611 90563128
Arthropathy 103.55 11.63 67 64641 366175 90197564
Osteopenia 102.59 11.63 103 64605 22899 90540840
Drug hypersensitivity 101.32 11.63 109 64599 463500 90100239
Metastases to central nervous system 98.09 11.63 89 64619 17453 90546286
Metastases to pleura 97.23 11.63 41 64667 2003 90561736
Pain in jaw 97.11 11.63 144 64564 47841 90515898
Bone disorder 96.70 11.63 100 64608 23020 90540719
Red blood cell count decreased 93.66 11.63 139 64569 46212 90517527
Lymphoedema 93.50 11.63 78 64630 13675 90550064
Intentional product use issue 92.04 11.63 21 64687 216871 90346868
Trigger finger 91.92 11.63 53 64655 5117 90558622
Type 2 diabetes mellitus 89.67 11.63 18 64690 203226 90360513
Ascites 89.14 11.63 138 64570 47602 90516137
Pneumonia haemophilus 88.05 11.63 35 64673 1468 90562271
Hypersensitivity 85.54 11.63 120 64588 454557 90109182
Metastatic neoplasm 84.65 11.63 49 64659 4766 90558973
Fibromyalgia 83.57 11.63 22 64686 206247 90357492
Breast cancer female 82.21 11.63 75 64633 14811 90548928
Polyneuropathy 81.51 11.63 84 64624 19257 90544482
Osteolysis 81.29 11.63 43 64665 3507 90560232
Acute myeloid leukaemia 78.72 11.63 85 64623 20555 90543184
Wheezing 78.25 11.63 36 64672 238044 90325695
C-reactive protein abnormal 77.81 11.63 3 64705 127426 90436313
Fracture 77.42 11.63 87 64621 21989 90541750
Joint range of motion decreased 77.10 11.63 5 64703 135638 90428101
Swelling 76.44 11.63 113 64595 418945 90144794
Tongue biting 76.25 11.63 35 64673 2098 90561641
Interstitial lung disease 75.62 11.63 168 64540 76237 90487502
Sleep disorder due to general medical condition, insomnia type 75.41 11.63 4 64704 128690 90435049
Palmar-plantar erythrodysaesthesia syndrome 74.60 11.63 96 64612 27927 90535812
Blister 71.56 11.63 47 64661 254951 90308788
Discomfort 71.17 11.63 55 64653 274280 90289459
Hepatic enzyme increased 71.06 11.63 92 64616 360644 90203095
Tonsillar disorder 70.45 11.63 28 64680 1174 90562565
Completed suicide 70.26 11.63 10 64698 145048 90418691
Metastases to pelvis 69.97 11.63 23 64685 553 90563186
Lacrimation increased 69.38 11.63 91 64617 26971 90536768
Sinusitis 69.14 11.63 86 64622 343002 90220737
Vitreoretinal traction syndrome 69.10 11.63 13 64695 20 90563719
Vulvovaginal dryness 68.64 11.63 38 64670 3393 90560346
Mouth haemorrhage 67.94 11.63 53 64655 8448 90555291
Off label use 67.93 11.63 485 64223 1101767 89461972
Abdominal discomfort 66.35 11.63 152 64556 477176 90086563
Injury 66.16 11.63 29 64679 197320 90366419
Mast cell activation syndrome 66.04 11.63 29 64679 1565 90562174
Ischaemic stroke 65.49 11.63 80 64628 22086 90541653
Neutrophil count decreased 64.93 11.63 152 64556 71380 90492359
Nasal disorder 64.60 11.63 36 64672 3256 90560483
Pleural effusion 64.35 11.63 201 64507 111790 90451949
Thrombocytopenia 64.09 11.63 307 64401 208418 90355321
Anaemia 63.89 11.63 451 64257 352351 90211388
PIK3CA-activated mutation 63.51 11.63 26 64682 1178 90562561
Invasive ductal breast carcinoma 63.04 11.63 49 64659 7769 90555970
Metastases to chest wall 62.68 11.63 22 64686 649 90563090
Product substitution issue 61.50 11.63 70 64638 17938 90545801
Malignant pleural effusion 59.77 11.63 33 64675 2931 90560808
Lip dry 59.58 11.63 3 64705 100952 90462787
Dysgeusia 59.41 11.63 122 64586 52438 90511301
Metastases to the mediastinum 59.30 11.63 21 64687 636 90563103
Sequestrectomy 59.20 11.63 22 64686 767 90562972
Product use issue 59.13 11.63 90 64618 329829 90233910
Facet joint syndrome 57.82 11.63 3 64705 98386 90465353
Organising pneumonia 57.77 11.63 46 64662 7551 90556188
Lower respiratory tract infection 56.87 11.63 57 64651 250602 90313137
Nausea 56.49 11.63 1108 63600 1109208 89454531
Retinal toxicity 56.11 11.63 25 64683 1397 90562342
Diarrhoea 54.59 11.63 957 63751 938233 89625506
Full blood count decreased 54.27 11.63 85 64623 29604 90534135
Gastrointestinal disorder 54.19 11.63 62 64646 256625 90307114
Liver injury 54.18 11.63 27 64681 170540 90393199
Osteomyelitis 54.10 11.63 82 64626 27764 90535975
Musculoskeletal toxicity 53.92 11.63 19 64689 567 90563172
Debridement 52.65 11.63 23 64685 1226 90562513
Cystoid macular oedema 52.56 11.63 27 64681 2073 90561666
Mobility decreased 52.46 11.63 61 64647 250673 90313066
Peritoneal disorder 52.14 11.63 19 64689 626 90563113
Prescribed overdose 51.56 11.63 5 64703 97620 90466119
Endometrial hyperplasia 51.16 11.63 21 64687 958 90562781
Madarosis 51.04 11.63 32 64676 3597 90560142
Product use in unapproved indication 50.91 11.63 102 64606 336134 90227605
Urticaria 49.85 11.63 92 64616 312642 90251097
Bone sequestrum 49.31 11.63 23 64685 1430 90562309
Chest wall mass 49.25 11.63 18 64690 598 90563141
Blood alkaline phosphatase increased 49.01 11.63 107 64601 47972 90515767
Dry skin 48.69 11.63 156 64552 87917 90475822
Condition aggravated 48.21 11.63 240 64468 595305 89968434
Bursitis 47.97 11.63 17 64691 131637 90432102
Peripheral venous disease 47.96 11.63 3 64705 83918 90479821
Wound infection 47.81 11.63 9 64699 106393 90457346
Breast mass 47.16 11.63 45 64663 9402 90554337
Breast pain 47.10 11.63 47 64661 10371 90553368
Ill-defined disorder 46.76 11.63 38 64670 184853 90378886
Confusional state 46.67 11.63 132 64576 386073 90177666
Pathological fracture 46.31 11.63 45 64663 9615 90554124
Tongue injury 46.09 11.63 17 64691 580 90563159
Pseudocellulitis 45.14 11.63 12 64696 133 90563606
Fasciitis 44.91 11.63 17 64691 624 90563115
Therapeutic product effect incomplete 44.07 11.63 44 64664 193852 90369887
Oestradiol increased 43.85 11.63 11 64697 95 90563644
Recall phenomenon 43.65 11.63 18 64690 831 90562908
Ovarian cancer 43.16 11.63 37 64671 6730 90557009
Metastases to abdominal wall 42.37 11.63 12 64696 171 90563568
Radiation skin injury 42.32 11.63 19 64689 1081 90562658
Prescribed underdose 41.94 11.63 3 64705 75016 90488723
Scan abnormal 41.42 11.63 16 64692 621 90563118
Osteosclerosis 41.34 11.63 30 64678 4290 90559449
Excessive eye blinking 41.31 11.63 20 64688 1352 90562387
Inflammation 41.20 11.63 40 64668 178552 90385187
Hair growth abnormal 40.91 11.63 28 64680 3648 90560091
Autoimmune disorder 40.35 11.63 4 64704 76740 90486999
Pleural neoplasm 39.76 11.63 14 64694 417 90563322
Gait inability 39.72 11.63 28 64680 146428 90417311
Leiomyosarcoma recurrent 39.39 11.63 7 64701 6 90563733
Peripheral swelling 39.10 11.63 157 64551 412949 90150790
Asthma 38.79 11.63 71 64637 242089 90321650
Nasopharyngitis 38.35 11.63 155 64553 406949 90156790
Decreased appetite 38.21 11.63 424 64284 376116 90187623
Musculoskeletal chest pain 37.98 11.63 64 64644 23686 90540053
Constipation 37.80 11.63 335 64373 280060 90283679
Obesity 37.80 11.63 14 64694 105493 90458246
Musculoskeletal stiffness 37.57 11.63 99 64609 296433 90267306
Oedema 37.46 11.63 53 64655 200242 90363497
Jaundice 37.36 11.63 76 64632 32441 90531298
Cholestasis 37.24 11.63 81 64627 36218 90527521
Grip strength decreased 37.24 11.63 10 64698 92566 90471173
Lymphadenopathy 36.97 11.63 93 64615 45682 90518057
Portal hypertension 36.90 11.63 29 64679 4672 90559067
Autoimmune hepatitis 36.65 11.63 41 64667 10310 90553429
Dental care 36.46 11.63 18 64690 1270 90562469
Mucosal inflammation 36.44 11.63 107 64601 57518 90506221
Metastases to soft tissue 36.41 11.63 12 64696 291 90563448
White blood cell disorder 36.40 11.63 24 64684 2940 90560799
Neoplasm malignant 36.37 11.63 77 64631 33803 90529936
Tendonitis 36.06 11.63 59 64649 21313 90542426
White blood cell count abnormal 36.05 11.63 35 64673 7469 90556270
Oral pain 35.92 11.63 75 64633 32608 90531131
Loss of personal independence in daily activities 35.64 11.63 27 64681 136078 90427661
Metastases to peritoneum 35.60 11.63 27 64681 4128 90559611
Hypertensive angiopathy 35.54 11.63 9 64699 81 90563658
Injection site reaction 35.10 11.63 11 64697 92069 90471670
Hormone receptor positive breast cancer 34.94 11.63 15 64693 766 90562973
C-reactive protein increased 34.92 11.63 47 64661 181342 90382397
Apocrine breast carcinoma 34.41 11.63 6 64702 4 90563735
Psoriasis 34.19 11.63 33 64675 147721 90416018
Gingival recession 34.04 11.63 19 64689 1724 90562015
Tooth loss 34.00 11.63 34 64674 7520 90556219
Acanthosis 33.96 11.63 11 64697 252 90563487
Soft tissue neoplasm 33.75 11.63 9 64699 101 90563638
Carpal tunnel syndrome 33.73 11.63 61 64647 23867 90539872
Drug intolerance 33.59 11.63 185 64523 447406 90116333
Neutrophil count abnormal 33.56 11.63 26 64682 4102 90559637
Oestrogen receptor assay positive 33.07 11.63 13 64695 529 90563210
Metastases to spinal cord 32.87 11.63 11 64697 280 90563459
Pulmonary mass 32.77 11.63 67 64641 28705 90535034
Blood alkaline phosphatase abnormal 32.54 11.63 17 64691 1351 90562388
Blood cholesterol increased 32.42 11.63 62 64646 207950 90355789
Blood albumin abnormal 32.35 11.63 16 64692 1133 90562606
Injection site erythema 32.18 11.63 15 64693 98487 90465252
Infection 32.16 11.63 141 64567 361953 90201786
Hepatic lesion 32.14 11.63 29 64679 5644 90558095
Uterine polyp 32.10 11.63 21 64687 2539 90561200
Back pain 32.09 11.63 357 64351 316818 90246921
Periodontal disease 31.64 11.63 18 64690 1694 90562045
Knee arthroplasty 31.60 11.63 10 64698 83172 90480567
Injection site pain 31.46 11.63 47 64661 173652 90390087
Resorption bone increased 31.46 11.63 16 64692 1203 90562536
Hyperparathyroidism primary 31.21 11.63 12 64696 460 90563279
Epistaxis 31.19 11.63 132 64576 84993 90478746
Gingival swelling 31.14 11.63 27 64681 4986 90558753
Mean cell volume increased 31.11 11.63 27 64681 4994 90558745
Neoplasm 31.07 11.63 35 64673 8868 90554871
Contusion 30.96 11.63 85 64623 251131 90312608
Gene mutation 30.50 11.63 19 64689 2111 90561628
Metastases to skin 30.42 11.63 19 64689 2121 90561618
Recurrent cancer 30.42 11.63 20 64688 2439 90561300
Radiation pneumonitis 30.27 11.63 18 64690 1840 90561899
Mouth swelling 30.24 11.63 28 64680 5634 90558105
Sialoadenitis 30.08 11.63 19 64689 2163 90561576
Road traffic accident 29.95 11.63 20 64688 107606 90456133
Pneumonitis 29.85 11.63 84 64624 44086 90519653
Exposed bone in jaw 29.56 11.63 21 64687 2905 90560834
Blood bilirubin abnormal 29.35 11.63 18 64690 1946 90561793
Metastases to thorax 29.26 11.63 10 64698 272 90563467
Toothache 29.24 11.63 55 64653 22175 90541564
Tooth disorder 29.23 11.63 67 64641 31023 90532716
Medication error 29.06 11.63 12 64696 84640 90479099
Thrombosis 28.74 11.63 116 64592 73135 90490604
Asthenia 28.45 11.63 537 64171 533214 90030525
Pancreatic neoplasm 28.30 11.63 14 64694 992 90562747
Carbohydrate antigen 27.29 increased 28.18 11.63 8 64700 115 90563624
Alopecia 28.10 11.63 503 64205 494568 90069171
Ovarian stromal hyperplasia 27.83 11.63 6 64702 24 90563715
Oestradiol abnormal 27.75 11.63 7 64701 62 90563677
Acute phase reaction 27.66 11.63 10 64698 322 90563417
Joint neoplasm 27.65 11.63 7 64701 63 90563676
Tumour marker decreased 27.55 11.63 7 64701 64 90563675
Retroperitoneal fibrosis 27.31 11.63 10 64698 334 90563405
Colitis ulcerative 27.28 11.63 5 64703 60261 90503478
Cardiotoxicity 27.20 11.63 37 64671 11352 90552387
Hepatotoxicity 26.98 11.63 83 64625 45759 90517980
Mood swings 26.95 11.63 51 64657 20651 90543088
Migraine 26.91 11.63 60 64648 190332 90373407
Blood creatinine increased 26.78 11.63 143 64565 101243 90462496
Therapy non-responder 26.74 11.63 35 64673 136669 90427070
Bone cancer metastatic 26.68 11.63 9 64699 235 90563504
Progesterone receptor assay positive 26.66 11.63 10 64698 358 90563381
Pleural disorder 26.38 11.63 12 64696 704 90563035
Gingivitis 26.36 11.63 33 64675 9336 90554403
Tumour marker abnormal 26.24 11.63 10 64698 374 90563365
Pain 26.24 11.63 528 64180 995813 89567926
Mean cell haemoglobin increased 26.24 11.63 22 64686 3883 90559856
Vitreous detachment 26.20 11.63 18 64690 2360 90561379
Drug abuse 26.19 11.63 13 64695 82334 90481405
Glomerular filtration rate increased 26.08 11.63 17 64691 2043 90561696
Bilirubin conjugated abnormal 26.06 11.63 7 64701 81 90563658
Cardiac failure 25.96 11.63 150 64558 109346 90454393
Spinal pain 25.89 11.63 43 64665 15724 90548015
Retinal detachment 25.85 11.63 28 64680 6794 90556945
Lung disorder 25.77 11.63 42 64666 149841 90413898
Pyrexia 25.76 11.63 325 64383 660160 89903579
Dysphagia 25.45 11.63 152 64556 112126 90451613
Bone density decreased 25.45 11.63 45 64663 17300 90546439
Metastases to retroperitoneum 25.09 11.63 8 64700 174 90563565
Nail infection 24.93 11.63 18 64690 2554 90561185
Fibrous histiocytoma 24.78 11.63 11 64697 609 90563130
Dislocation of vertebra 24.58 11.63 5 64703 55963 90507776
Gamma-glutamyltransferase increased 24.50 11.63 71 64637 37881 90525858
Haemorrhoids 24.50 11.63 57 64651 26645 90537094
Blood calcium abnormal 24.26 11.63 16 64692 1961 90561778
Dyspnoea exertional 24.12 11.63 109 64599 72179 90491560
Weight increased 24.11 11.63 187 64521 417740 90145999
Urinary casts present 24.08 11.63 7 64701 110 90563629
Pulmonary fibrosis 23.73 11.63 25 64683 107478 90456261
Lymphadenopathy mediastinal 23.71 11.63 19 64689 3148 90560591
Peripheral sensory neuropathy 23.54 11.63 31 64677 9219 90554520
Laryngitis 23.43 11.63 4 64704 50749 90512990
Skin atrophy 23.27 11.63 24 64684 5505 90558234
Hepatic cyst 23.23 11.63 26 64682 6542 90557197
Bone debridement 23.22 11.63 8 64700 223 90563516
Full blood count abnormal 23.18 11.63 68 64640 36529 90527210
Haemoglobin decreased 23.11 11.63 196 64512 161760 90401979
Papilloedema 23.07 11.63 22 64686 4593 90559146
Sciatica 23.04 11.63 23 64685 101359 90462380
Adverse event 23.03 11.63 30 64678 117388 90446351
Platelet count decreased 22.95 11.63 172 64536 136797 90426942
Hair texture abnormal 22.78 11.63 22 64686 4665 90559074
Vitamin D deficiency 22.55 11.63 43 64665 17513 90546226
Aspartate aminotransferase increased 22.47 11.63 138 64570 102799 90460940
Acquired gene mutation 22.44 11.63 13 64695 1266 90562473
Intraductal proliferative breast lesion 22.27 11.63 19 64689 3434 90560305
Ebola disease 22.21 11.63 4 64704 4 90563735
Catheter site bruise 22.19 11.63 10 64698 574 90563165
Hypophosphatasia 22.13 11.63 6 64702 72 90563667
Toxicity to various agents 22.11 11.63 118 64590 287728 90276011
Hair colour changes 22.07 11.63 19 64689 3475 90560264
Chronic inflammatory demyelinating polyradiculoneuropathy 22.06 11.63 12 64696 1035 90562704
Menopausal symptoms 22.05 11.63 18 64690 3060 90560679
Tumour flare 22.00 11.63 10 64698 586 90563153
Atypical femur fracture 21.99 11.63 25 64683 6396 90557343
Superinfection 21.88 11.63 18 64690 3094 90560645
Alanine aminotransferase increased 21.79 11.63 152 64556 118186 90445553
Carcinoembryonic antigen increased 21.76 11.63 16 64692 2334 90561405
Joint dislocation 21.75 11.63 3 64705 44579 90519160
Metastases to bone marrow 21.63 11.63 10 64698 609 90563130
Transaminases increased 21.58 11.63 67 64641 37125 90526614
Abdominal pain upper 21.53 11.63 144 64564 332530 90231209
Hip arthroplasty 21.42 11.63 14 64694 76194 90487545
Jaw disorder 21.38 11.63 23 64685 5536 90558203
Neuralgia 21.38 11.63 60 64648 31440 90532299
Injection site pruritus 21.30 11.63 6 64702 53828 90509911
Overdose 21.24 11.63 51 64657 157658 90406081
Jaw operation 21.23 11.63 11 64697 860 90562879
Neoplasm recurrence 21.15 11.63 18 64690 3241 90560498
Uterine leiomyoma 21.11 11.63 32 64676 10832 90552907
Human epidermal growth factor receptor negative 20.98 11.63 5 64703 34 90563705
Endometrial hypertrophy 20.82 11.63 8 64700 306 90563433
Polymyositis 20.55 11.63 15 64693 2164 90561575
Invasive breast carcinoma 20.45 11.63 11 64697 928 90562811
Onychomadesis 20.43 11.63 4 64704 45994 90517745
Tongue neoplasm malignant stage unspecified 20.42 11.63 11 64697 930 90562809
Transient acantholytic dermatosis 20.37 11.63 6 64702 99 90563640
Decreased immune responsiveness 20.26 11.63 28 64680 8720 90555019
Cough 20.25 11.63 373 64335 368589 90195150
Hiccups 20.23 11.63 17 64691 3009 90560730
Blood lactate dehydrogenase increased 20.22 11.63 52 64656 25880 90537859
Atrophic vulvovaginitis 20.12 11.63 14 64694 1873 90561866
Metastases to adrenals 20.03 11.63 11 64697 967 90562772
Haemoglobin abnormal 19.96 11.63 25 64683 7075 90556664
General physical health deterioration 19.96 11.63 160 64548 354955 90208784
Nail avulsion 19.94 11.63 8 64700 344 90563395
Glomerulonephritis rapidly progressive 19.73 11.63 12 64696 1278 90562461
Red blood cell sedimentation rate increased 19.63 11.63 18 64690 82577 90481162
Autoimmune pancreatitis 19.61 11.63 8 64700 359 90563380
Bone marrow failure 19.58 11.63 59 64649 32162 90531577
Cardiomyopathy 19.50 11.63 44 64664 20162 90543577
Blood copper increased 19.45 11.63 4 64704 12 90563727
Visual acuity reduced 19.36 11.63 48 64660 23362 90540377
Antisynthetase syndrome 19.15 11.63 6 64702 123 90563616
Vertebral column mass 19.11 11.63 7 64701 234 90563505
Ageusia 18.98 11.63 38 64670 16038 90547701
Vascular purpura 18.78 11.63 13 64695 1725 90562014
Neuroectodermal neoplasm 18.74 11.63 3 64705 0 90563739
Hypotension 18.56 11.63 146 64562 325251 90238488
Periprosthetic metallosis 18.56 11.63 4 64704 16 90563723
Pulmonary embolism 18.49 11.63 158 64550 130662 90433077
Disease recurrence 18.41 11.63 64 64644 37589 90526150
Breast operation 18.35 11.63 9 64699 626 90563113
Axillary mass 18.18 11.63 9 64699 639 90563100
Cutaneous vasculitis 18.14 11.63 24 64684 7169 90556570
Osteoradionecrosis 18.03 11.63 6 64702 150 90563589
Cytopenia 17.97 11.63 39 64669 17410 90546329
Bacteriuria 17.88 11.63 11 64697 1195 90562544
Benign lymph node neoplasm 17.83 11.63 4 64704 20 90563719
Hyperthyroidism 17.81 11.63 40 64668 18270 90545469
Hip fracture 17.74 11.63 58 64650 33019 90530720
HER2 positive breast cancer 17.71 11.63 8 64700 462 90563277
Menopausal disorder 17.61 11.63 5 64703 72 90563667
Borrelia infection 17.55 11.63 7 64701 296 90563443
Blood creatinine abnormal 17.41 11.63 18 64690 4139 90559600
Delirium 17.23 11.63 30 64678 104329 90459410
Henoch-Schonlein purpura 17.18 11.63 12 64696 1615 90562124
COVID-19 17.03 11.63 190 64518 168653 90395086
Septic shock 17.02 11.63 21 64687 84139 90479600
Osteitis 17.01 11.63 17 64691 3756 90559983
Plantar fasciitis 17.00 11.63 18 64690 4256 90559483
Metastases to thyroid 16.94 11.63 4 64704 26 90563713
Menopause 16.92 11.63 16 64692 3305 90560434
Invasive lobular breast carcinoma 16.84 11.63 10 64698 1019 90562720
Ear infection 16.82 11.63 15 64693 69760 90493979
Tachycardia 16.81 11.63 57 64651 157616 90406123
Hospitalisation 16.79 11.63 42 64666 128058 90435681
Respiratory disorder 16.78 11.63 13 64695 64803 90498936
Purulent discharge 16.77 11.63 20 64688 5385 90558354
Periodontitis 16.71 11.63 17 64691 3836 90559903
Alanine aminotransferase abnormal 16.70 11.63 20 64688 5406 90558333
Cauda equina syndrome 16.62 11.63 11 64697 1356 90562383
Oroantral fistula 16.57 11.63 6 64702 194 90563545
Left ventricular dysfunction 16.51 11.63 34 64674 14635 90549104
Deep vein thrombosis 16.46 11.63 117 64591 91503 90472236
Portal fibrosis 16.43 11.63 7 64701 351 90563388
Mitral valve incompetence 16.37 11.63 44 64664 22480 90541259
Mastitis 16.37 11.63 15 64693 2978 90560761
Metastases to eye 16.31 11.63 6 64702 203 90563536
Sedation 16.26 11.63 7 64701 48164 90515575
High-pitched crying 16.22 11.63 4 64704 32 90563707
Anti-neutrophil cytoplasmic antibody positive vasculitis 16.21 11.63 17 64691 3976 90559763
Suicide attempt 16.13 11.63 18 64690 75381 90488358
Cancer pain 16.09 11.63 17 64691 4008 90559731
Phlebitis 16.05 11.63 23 64685 7407 90556332
Atrial enlargement 16.01 11.63 7 64701 374 90563365
Dental caries 16.00 11.63 29 64679 11368 90552371
Acute promyelocytic leukaemia 15.99 11.63 10 64698 1119 90562620
Actinomycosis 15.93 11.63 10 64698 1126 90562613
Impaired healing 15.84 11.63 100 64608 234099 90329640
Follicular lymphoma 15.82 11.63 7 64701 385 90563354
Postoperative wound complication 15.76 11.63 10 64698 1147 90562592
Femur fracture 15.76 11.63 70 64638 46012 90517727
Breast haemorrhage 15.63 11.63 6 64702 229 90563510
Burn oesophageal 15.56 11.63 7 64701 400 90563339
Injection site bruising 15.55 11.63 9 64699 52298 90511441
Genital atrophy 15.45 11.63 3 64705 6 90563733
Metastases to uterus 15.42 11.63 5 64703 115 90563624
Oral disorder 15.39 11.63 27 64681 10318 90553421
Eastern Cooperative Oncology Group performance status worsened 15.30 11.63 12 64696 1927 90561812
Ovarian neoplasm 15.17 11.63 9 64699 916 90562823
Hypoaesthesia teeth 15.07 11.63 4 64704 44 90563695
Hyperglycaemia 14.92 11.63 74 64634 50896 90512843
Sensitive skin 14.82 11.63 15 64693 3366 90560373
Depressed mood 14.76 11.63 73 64635 50149 90513590
Bone cancer 14.68 11.63 11 64697 1651 90562088
Therapeutic response decreased 14.63 11.63 26 64682 89703 90474036
Metabolic acidosis 14.63 11.63 11 64697 55665 90508074
Rash 14.61 11.63 445 64263 795655 89768084
Nail dystrophy 14.58 11.63 10 64698 1308 90562431
Bronchitis 14.52 11.63 58 64650 152869 90410870
Bone loss 14.41 11.63 15 64693 3477 90560262
Ear pain 14.40 11.63 12 64696 57690 90506049
Paratracheal lymphadenopathy 14.39 11.63 4 64704 53 90563686
Malaise 14.35 11.63 314 64394 585672 89978067
Radicular pain 14.11 11.63 7 64701 499 90563240
Subacute cutaneous lupus erythematosus 14.09 11.63 15 64693 3567 90560172
Obstructive nephropathy 13.92 11.63 3 64705 12 90563727
Pelvic mass 13.90 11.63 10 64698 1411 90562328
Product quality issue 13.84 11.63 22 64686 79303 90484436
Intentional overdose 13.73 11.63 29 64679 93805 90469934
Vertigo 13.64 11.63 91 64617 69720 90494019
Cardio-respiratory arrest 13.58 11.63 15 64693 63125 90500614
Malignant neoplasm of pleura 13.58 11.63 4 64704 66 90563673
Pelvic bone injury 13.58 11.63 4 64704 66 90563673
Loose tooth 13.55 11.63 15 64693 3728 90560011
Bladder irritation 13.54 11.63 6 64702 331 90563408
Chronic hepatitis 13.41 11.63 9 64699 1136 90562603
Squamous cell breast carcinoma 13.37 11.63 3 64705 15 90563724
Bone marrow infiltration 13.31 11.63 8 64700 834 90562905
Incorrect route of product administration 13.30 11.63 10 64698 50616 90513123
Cardiac arrest 13.30 11.63 35 64673 104900 90458839
Bone erosion 13.27 11.63 11 64697 53010 90510729
Flushing 13.24 11.63 27 64681 88464 90475275
Injection site swelling 13.11 11.63 14 64694 59825 90503914
Hydronephrosis 13.09 11.63 28 64680 12374 90551365
Decreased vibratory sense 13.08 11.63 6 64702 359 90563380
Vitreous adhesions 13.05 11.63 4 64704 76 90563663
Ovarian mass 13.01 11.63 8 64700 869 90562870
Blood pressure fluctuation 12.96 11.63 11 64697 52402 90511337
Meningioma 12.91 11.63 17 64691 5054 90558685
Multiple sclerosis relapse 12.91 11.63 11 64697 52294 90511445
Electrocardiogram QT interval 12.90 11.63 5 64703 196 90563543
Oedema mucosal 12.87 11.63 9 64699 1214 90562525
Oral surgery 12.86 11.63 10 64698 1586 90562153
Acquired porokeratosis 12.77 11.63 3 64705 19 90563720
Night sweats 12.76 11.63 48 64660 128718 90435021
Poor peripheral circulation 12.66 11.63 15 64693 4010 90559729
Amyotrophy 12.64 11.63 5 64703 207 90563532
Diabetic hyperosmolar coma 12.61 11.63 6 64702 390 90563349
Metastases to breast 12.57 11.63 6 64702 393 90563346
Renal pain 12.53 11.63 21 64687 7738 90556001
Oral cavity fistula 12.52 11.63 7 64701 637 90563102
Hypercholesterolaemia 12.52 11.63 34 64674 100858 90462881
Tricuspid valve incompetence 12.48 11.63 33 64675 16698 90547041
Hypercalcaemia 12.46 11.63 53 64655 34187 90529552
Dysaesthesia 12.44 11.63 17 64691 5238 90558501
Mastectomy 12.43 11.63 11 64697 2088 90561651
Intestinal metastasis 12.39 11.63 5 64703 218 90563521
Chronic hepatic failure 12.37 11.63 7 64701 652 90563087
Musculoskeletal discomfort 12.35 11.63 38 64670 20953 90542786
Paraneoplastic syndrome 12.32 11.63 7 64701 657 90563082
Nail toxicity 12.30 11.63 6 64702 412 90563327
Device issue 12.24 11.63 3 64705 29534 90534205
Hypertensive crisis 12.19 11.63 34 64674 17750 90545989
Unresponsive to stimuli 12.15 11.63 6 64702 38115 90525624
Breast cancer stage II 12.14 11.63 5 64703 35329 90528410
Exostosis 12.13 11.63 12 64696 53122 90510617
Intentional self-injury 12.12 11.63 3 64705 29331 90534408
Breast cancer in situ 12.10 11.63 10 64698 1730 90562009
Romberg test positive 12.06 11.63 5 64703 234 90563505
Urinary tract infection staphylococcal 12.00 11.63 6 64702 435 90563304
Foot deformity 11.94 11.63 15 64693 59636 90504103
Heart rate increased 11.91 11.63 41 64667 112861 90450878
Hepatic failure 11.86 11.63 58 64650 39670 90524069
Skin mass 11.85 11.63 20 64688 7410 90556329
Ventricular extrasystoles 11.85 11.63 28 64680 13222 90550517
Tendon pain 11.84 11.63 14 64694 3734 90560005
Cerebral microhaemorrhage 11.82 11.63 5 64703 246 90563493
Electrocardiogram QT interval abnormal 11.80 11.63 5 64703 247 90563492
Hepatic steatosis 11.80 11.63 55 64653 36890 90526849
Cerebral thrombosis 11.79 11.63 10 64698 1793 90561946
Reflux gastritis 11.76 11.63 9 64699 1395 90562344
Varicophlebitis 11.75 11.63 3 64705 28 90563711
Nail discolouration 11.75 11.63 13 64695 3229 90560510
Gingival ulceration 11.73 11.63 8 64700 1036 90562703
Blood testosterone increased 11.71 11.63 5 64703 252 90563487
Cutaneous sarcoidosis 11.70 11.63 6 64702 459 90563280
Polypectomy 11.69 11.63 8 64700 1042 90562697
Lung neoplasm malignant 11.64 11.63 41 64667 24232 90539507

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Secondary hypogonadism 104.91 22.78 21 2832 765 42617717
Mesenteric vein thrombosis 84.09 22.78 18 2835 914 42617568
Performance enhancing product use 79.20 22.78 13 2840 149 42618333
Growth retardation 76.45 22.78 20 2833 2412 42616070
Blood testosterone increased 74.78 22.78 18 2835 1549 42616933
Andropause 68.94 22.78 11 2842 104 42618378
Insulin-like growth factor increased 63.95 22.78 16 2837 1615 42616867
Tibia fracture 57.29 22.78 15 2838 1813 42616669
Cardiac valve fibroelastoma 46.82 22.78 7 2846 41 42618441
Metastases to bone 44.18 22.78 21 2832 14788 42603694
Postprandial hypoglycaemia 42.50 22.78 7 2846 82 42618400
Irritable bowel syndrome 39.54 22.78 14 2839 4667 42613815
Haematocrit increased 39.15 22.78 12 2841 2555 42615927
Intentional product misuse 37.70 22.78 32 2821 61868 42556614
Product use issue 37.45 22.78 35 2818 76716 42541766
Spondylolisthesis 36.83 22.78 9 2844 824 42617658
Glucose tolerance decreased 36.29 22.78 6 2847 72 42618410
Peptic ulcer 35.79 22.78 12 2841 3400 42615082
Breast cancer recurrent 35.22 22.78 5 2848 19 42618463
Libido decreased 34.69 22.78 13 2840 5085 42613397
Blood growth hormone increased 33.84 22.78 8 2845 636 42617846
Polycythaemia 33.68 22.78 11 2842 2875 42615607
Autoimmune thyroiditis 31.10 22.78 9 2844 1573 42616909
Oestradiol increased 30.09 22.78 5 2848 62 42618420
Off label use 29.22 22.78 101 2752 638234 41980248
Hypothalamic pituitary adrenal axis suppression 28.17 22.78 6 2847 297 42618185
Hypercoagulation 27.25 22.78 8 2845 1471 42617011
High density lipoprotein decreased 26.74 22.78 10 2843 3887 42614595
Drug dose omission by device 26.04 22.78 11 2842 5875 42612607
Disorder of sex development 25.84 22.78 3 2850 0 42618482
Epiphyseal fracture 25.84 22.78 3 2850 0 42618482
Cardiac ventricular thrombosis 25.60 22.78 8 2845 1814 42616668
Portal vein thrombosis 25.24 22.78 10 2843 4539 42613943
Atypical fracture 25.10 22.78 5 2848 177 42618305
Osteonecrosis of jaw 23.28 22.78 15 2838 19034 42599448

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 946.91 12.20 407 53276 30965 110504651
Malignant neoplasm progression 552.34 12.20 543 53140 174024 110361592
Metastases to liver 483.32 12.20 267 53416 35119 110500497
Metastases to lung 437.86 12.20 217 53466 22846 110512770
Hot flush 435.32 12.20 314 53369 65722 110469894
Breast cancer recurrent 356.74 12.20 114 53569 3732 110531884
Breast cancer metastatic 320.62 12.20 140 53543 11041 110524575
Neoplasm progression 315.47 12.20 257 53426 64338 110471278
Breast cancer 297.63 12.20 202 53481 38340 110497276
White blood cell count decreased 281.11 12.20 443 53240 228947 110306669
Bone pain 252.45 12.20 227 53456 64906 110470710
Osteonecrosis 230.42 12.20 164 53519 33577 110502039
Fatigue 228.84 12.20 1177 52506 1214781 109320835
Neutropenia 219.92 12.20 530 53153 374090 110161526
Osteonecrosis of jaw 203.34 12.20 176 53507 47841 110487775
Arthralgia 198.24 12.20 825 52858 778807 109756809
Metastases to lymph nodes 195.83 12.20 110 53573 14922 110520694
Tumour marker increased 180.51 12.20 74 53609 4986 110530630
Disease progression 178.53 12.20 377 53306 243657 110291959
Ejection fraction decreased 161.38 12.20 144 53539 40736 110494880
Pseudocirrhosis 149.17 12.20 42 53641 881 110534735
Human rhinovirus test positive 149.16 12.20 45 53638 1212 110534404
Respiratory syncytial virus test positive 145.64 12.20 46 53637 1448 110534168
Carbohydrate antigen 15-3 increased 138.83 12.20 45 53638 1542 110534074
Metastases to spine 134.25 12.20 61 53622 5282 110530334
Tooth extraction 129.60 12.20 80 53603 12911 110522705
Second primary malignancy 121.45 12.20 87 53596 17981 110517635
Drug ineffective 120.26 12.20 361 53322 1520179 109015437
Osteopenia 116.09 12.20 92 53591 22117 110513499
Bone lesion 115.00 12.20 60 53623 7027 110528589
Infusion related reaction 112.25 12.20 24 53659 381138 110154478
Viral test positive 110.96 12.20 33 53650 845 110534771
Synovitis 108.61 12.20 6 53677 274086 110261530
Maternal exposure during pregnancy 102.82 12.20 5 53678 254878 110280738
Systemic lupus erythematosus 96.50 12.20 7 53676 254331 110281285
Alopecia 93.87 12.20 388 53295 364365 110171251
Neuropathy peripheral 92.75 12.20 242 53441 179035 110356581
Lymphoedema 89.30 12.20 67 53616 14862 110520754
Pneumonia haemophilus 84.40 12.20 36 53647 2679 110532937
Trigger finger 82.31 12.20 43 53640 5049 110530567
Tongue biting 81.65 12.20 36 53647 2903 110532713
Completed suicide 80.70 12.20 11 53672 242370 110293246
Metastases to central nervous system 79.57 12.20 75 53608 22742 110512874
Myalgia 79.37 12.20 263 53420 222118 110313498
Nausea 79.14 12.20 931 52752 1234759 109300857
Tonsillar disorder 75.12 12.20 28 53655 1461 110534155
Invasive ductal breast carcinoma 74.21 12.20 44 53639 6602 110529014
Treatment failure 72.85 12.20 22 53661 277212 110258404
Therapeutic product effect decreased 72.68 12.20 15 53668 244301 110291315
Metastasis 72.68 12.20 47 53636 8220 110527396
Vitreoretinal traction syndrome 72.27 12.20 13 53670 25 110535591
Pain in jaw 69.81 12.20 104 53579 51073 110484543
Folliculitis 68.54 12.20 3 53680 167650 110367966
Red blood cell count decreased 68.05 12.20 118 53565 65805 110469811
Vulvovaginal dryness 67.87 12.20 31 53652 2716 110532900
Mouth haemorrhage 66.50 12.20 54 53629 13434 110522182
Lacrimation increased 65.53 12.20 78 53605 30872 110504744
Intentional product use issue 64.54 12.20 20 53663 247886 110287730
Metastases to pleura 62.96 12.20 27 53656 2036 110533580
Pericarditis 62.06 12.20 15 53668 219099 110316517
Retinal toxicity 61.70 12.20 25 53658 1634 110533982
Secondary hypogonadism 61.63 12.20 21 53662 842 110534774
Bone disorder 61.48 12.20 63 53620 21129 110514487
Joint swelling 61.18 12.20 75 53608 442770 110092846
Psoriatic arthropathy 60.81 12.20 11 53672 196750 110338866
Osteolysis 60.20 12.20 36 53647 5487 110530129
Full blood count decreased 60.05 12.20 76 53607 32023 110503593
Diarrhoea 59.46 12.20 827 52856 1138678 109396938
Endometrial hyperplasia 57.74 12.20 19 53664 683 110534933
Drug hypersensitivity 57.52 12.20 82 53601 454008 110081608
Muscle injury 56.01 12.20 3 53680 140804 110394812
Toxicity to various agents 55.86 12.20 92 53591 480463 110055153
Cystoid macular oedema 55.07 12.20 27 53656 2773 110532843
Peritoneal disorder 54.71 12.20 19 53664 807 110534809
Rheumatoid arthritis 53.91 12.20 40 53643 299573 110236043
Malignant pleural effusion 53.43 12.20 30 53653 4063 110531553
Nasal disorder 52.49 12.20 30 53653 4204 110531412
C-reactive protein abnormal 50.86 12.20 3 53680 129692 110405924
Mast cell activation syndrome 49.96 12.20 21 53662 1507 110534109
Palmar-plantar erythrodysaesthesia syndrome 49.81 12.20 79 53604 40946 110494670
Breast mass 49.72 12.20 37 53646 8104 110527512
Ischaemic stroke 49.47 12.20 79 53604 41184 110494432
Wheezing 48.66 12.20 32 53651 255198 110280418
Product substitution issue 48.63 12.20 58 53625 23003 110512613
Type 2 diabetes mellitus 48.52 12.20 13 53670 177219 110358397
Wound 48.03 12.20 27 53656 234410 110301206
Off label use 47.48 12.20 483 53200 1499702 109035914
Breast cancer female 47.38 12.20 43 53640 12425 110523191
Andropause 47.18 12.20 11 53672 104 110535512
Breast pain 47.13 12.20 39 53644 9961 110525655
Ascites 46.66 12.20 124 53559 92684 110442932
Acute myeloid leukaemia 45.74 12.20 73 53610 38037 110497579
Pleural neoplasm 45.61 12.20 14 53669 400 110535216
Fasciitis 44.60 12.20 17 53666 944 110534672
Glossodynia 43.46 12.20 27 53656 221977 110313639
Confusional state 43.03 12.20 103 53580 468577 110067039
Metastases to chest wall 42.67 12.20 15 53668 661 110534955
Oestradiol increased 41.94 12.20 10 53673 105 110535511
Joint range of motion decreased 41.82 12.20 5 53678 121827 110413789
Recall phenomenon 41.71 12.20 18 53665 1378 110534238
Blood testosterone increased 41.64 12.20 18 53665 1384 110534232
Mesenteric vein thrombosis 41.53 12.20 20 53663 1975 110533641
Oral pain 41.25 12.20 69 53614 37375 110498241
Tongue injury 39.80 12.20 14 53669 618 110534998
Metastases to pelvis 39.28 12.20 15 53668 837 110534779
White blood cell disorder 39.09 12.20 24 53659 3835 110531781
Uterine polyp 38.63 12.20 19 53664 1964 110533652
Bursitis 38.58 12.20 8 53675 129910 110405706
Arthropathy 38.32 12.20 50 53633 287472 110248144
Dry skin 38.09 12.20 127 53556 107526 110428090
Oestrogen receptor assay positive 38.07 12.20 12 53671 375 110535241
Hypertensive angiopathy 37.70 12.20 9 53674 95 110535521
Fibromyalgia 37.50 12.20 18 53665 170891 110364725
Lip dry 37.25 12.20 3 53680 100080 110435536
Interstitial lung disease 37.17 12.20 150 53533 139184 110396432
Sleep disorder due to general medical condition, insomnia type 37.10 12.20 4 53679 105639 110429977
Apocrine breast carcinoma 36.72 12.20 6 53677 4 110535612
Metastases to the mediastinum 36.70 12.20 14 53669 779 110534837
Dysgeusia 36.70 12.20 95 53588 69890 110465726
Pseudocellulitis 36.43 12.20 12 53671 433 110535183
Ovarian cancer 36.22 12.20 24 53659 4372 110531244
Hypersensitivity 36.12 12.20 90 53593 403908 110131708
Sialoadenitis 36.01 12.20 20 53663 2653 110532963
Hair growth abnormal 35.83 12.20 22 53661 3515 110532101
Dental care 35.71 12.20 15 53668 1074 110534542
Musculoskeletal chest pain 35.64 12.20 56 53627 28791 110506825
Carpal tunnel syndrome 35.30 12.20 49 53634 22561 110513055
Amaurosis fugax 35.29 12.20 19 53664 2371 110533245
Febrile neutropenia 34.63 12.20 63 53620 316704 110218912
Metastases to breast 34.30 12.20 11 53672 364 110535252
Sinusitis 34.26 12.20 57 53626 296631 110238985
Injury 34.08 12.20 22 53661 177243 110358373
Excessive eye blinking 33.72 12.20 17 53666 1853 110533763
Decreased appetite 33.62 12.20 366 53317 475480 110060136
Osteosclerosis 33.27 12.20 23 53660 4492 110531124
Mouth swelling 33.25 12.20 28 53655 7326 110528290
Product use in unapproved indication 33.14 12.20 109 53574 447268 110088348
Radiation skin injury 32.88 12.20 16 53667 1616 110534000
Soft tissue neoplasm 32.13 12.20 8 53675 102 110535514
C-reactive protein increased 32.12 12.20 35 53648 217884 110317732
Neutrophil count decreased 32.10 12.20 130 53553 120811 110414805
Irritable bowel syndrome 32.09 12.20 20 53663 164195 110371421
Hypotension 32.07 12.20 138 53545 523711 110011905
Leiomyosarcoma recurrent 32.00 12.20 6 53677 16 110535600
Inflammation 31.99 12.20 28 53655 193210 110342406
General physical health deterioration 31.93 12.20 103 53580 425192 110110424
Nail infection 31.84 12.20 18 53665 2470 110533146
Asthenia 31.81 12.20 490 53193 688509 109847107
Back pain 31.80 12.20 297 53386 370699 110164917
Carbohydrate antigen 27.29 increased 31.71 12.20 8 53675 108 110535508
Cardiac valve fibroelastoma 31.64 12.20 7 53676 51 110535565
Prescribed overdose 31.58 12.20 3 53680 87578 110448038
Hepatic enzyme increased 31.48 12.20 68 53615 320824 110214792
Portal hypertension 31.28 12.20 29 53654 8608 110527008
Atypical femur fracture 30.87 12.20 25 53658 6194 110529422
Autoimmune hepatitis 30.83 12.20 37 53646 14767 110520849
Metastases to soft tissue 30.80 12.20 12 53671 707 110534909
Resorption bone increased 30.79 12.20 15 53668 1519 110534097
Debridement 30.72 12.20 16 53667 1867 110533749
Vitreous detachment 30.69 12.20 18 53665 2647 110532969
Hyperparathyroidism primary 30.59 12.20 11 53672 518 110535098
Progesterone receptor assay positive 30.39 12.20 9 53674 227 110535389
Joint neoplasm 30.33 12.20 7 53676 63 110535553
Pleural effusion 30.31 12.20 168 53515 177541 110358075
Ovarian stromal hyperplasia 30.14 12.20 6 53677 24 110535592
Metastatic neoplasm 29.99 12.20 24 53659 5849 110529767
Tendonitis 29.98 12.20 49 53634 26034 110509582
Human epidermal growth factor receptor negative 29.69 12.20 5 53678 5 110535611
Septic shock 29.68 12.20 20 53663 157508 110378108
Intraductal proliferative breast lesion 29.25 12.20 18 53665 2887 110532729
Swelling 29.24 12.20 81 53602 350960 110184656
Sequestrectomy 29.05 12.20 12 53671 824 110534792
Nail avulsion 28.77 12.20 8 53675 160 110535456
Performance enhancing product use 28.54 12.20 8 53675 165 110535451
Urticaria 28.51 12.20 71 53612 318786 110216830
Leukopenia 28.33 12.20 145 53538 148646 110386970
Pathological fracture 28.28 12.20 32 53651 12000 110523616
Tooth disorder 28.10 12.20 51 53632 29458 110506158
Pyrexia 27.96 12.20 290 53393 897975 109637641
Acute phase reaction 27.85 12.20 10 53673 469 110535147
Bone cancer metastatic 27.64 12.20 9 53674 313 110535303
Bone sequestrum 27.62 12.20 13 53670 1220 110534396
Polycythaemia 27.27 12.20 18 53665 3257 110532359
Osteomyelitis 27.23 12.20 57 53626 36543 110499073
Periodontal disease 26.88 12.20 15 53668 2007 110533609
Metastases to peritoneum 26.69 12.20 22 53661 5588 110530028
Cholestasis 26.37 12.20 80 53603 64438 110471178
Obesity 26.33 12.20 11 53672 113340 110422276
Pleural disorder 26.32 12.20 12 53671 1047 110534569
Urinary casts present 26.30 12.20 7 53676 118 110535498
Invasive breast carcinoma 26.24 12.20 11 53672 784 110534832
Tumour marker decreased 26.00 12.20 6 53677 54 110535562
Blister 25.95 12.20 44 53639 227332 110308284
Urinary tract disorder 25.90 12.20 22 53661 5822 110529794
Catheter site bruise 25.80 12.20 10 53673 581 110535035
Oedema 25.50 12.20 39 53644 209937 110325679
Papilloedema 25.15 12.20 24 53659 7385 110528231
Overdose 25.10 12.20 47 53636 233747 110301869
Metastases to skin 25.09 12.20 15 53668 2284 110533332
Mood swings 25.07 12.20 42 53641 22770 110512846
Medication error 24.84 12.20 10 53673 105356 110430260
Gingival recession 24.83 12.20 13 53670 1533 110534083
Wound infection 24.71 12.20 8 53675 96457 110439159
Colitis ulcerative 24.61 12.20 4 53679 77359 110458257
Asthma 24.57 12.20 53 53630 250238 110285378
PIK3CA-activated mutation 24.54 12.20 10 53673 663 110534953
Blood alkaline phosphatase increased 24.48 12.20 83 53600 70852 110464764
Hair texture abnormal 24.21 12.20 18 53665 3936 110531680
Glucose tolerance decreased 24.21 12.20 6 53677 75 110535541
Condition aggravated 24.20 12.20 234 53449 734602 109801014
Postprandial hypoglycaemia 24.17 12.20 7 53676 163 110535453
Femur fracture 23.97 12.20 61 53622 44408 110491208
Organising pneumonia 23.95 12.20 32 53651 14211 110521405
Menopausal symptoms 23.93 12.20 15 53668 2486 110533130
Neoplasm 23.56 12.20 28 53655 11059 110524557
Gait inability 23.51 12.20 19 53664 136357 110399259
Discomfort 23.19 12.20 43 53640 214664 110320952
Therapeutic product effect incomplete 23.15 12.20 46 53637 223759 110311857
Gastrointestinal disorder 23.12 12.20 52 53631 241900 110293716
Bilirubin conjugated abnormal 23.04 12.20 7 53676 193 110535423
Mean cell volume increased 22.79 12.20 24 53659 8306 110527310
Pancreatic neoplasm 22.78 12.20 13 53670 1816 110533800
Metabolic acidosis 22.66 12.20 10 53673 99734 110435882
Hormone receptor positive breast cancer 22.51 12.20 9 53674 568 110535048
Vaginal discharge 22.45 12.20 35 53648 17873 110517743
Fibrous histiocytoma 22.42 12.20 10 53673 829 110534787
Uterine leiomyoma 22.28 12.20 23 53660 7777 110527839
Carcinoembryonic antigen increased 22.26 12.20 15 53668 2809 110532807
Neoplasm malignant 22.19 12.20 53 53630 37090 110498526
Recurrent cancer 21.90 12.20 16 53667 3407 110532209
Lower respiratory tract infection 21.83 12.20 54 53629 243052 110292564
Madarosis 21.73 12.20 16 53667 3447 110532169
Prescribed underdose 21.58 12.20 3 53680 65171 110470445
Cough 21.53 12.20 329 53354 461312 110074304
Bone debridement 21.53 12.20 8 53675 414 110535202
Metastases to retroperitoneum 21.42 12.20 8 53675 420 110535196
Oestradiol abnormal 21.37 12.20 5 53678 48 110535568
Liver injury 21.24 12.20 25 53658 150388 110385228
Hypophosphatasia 21.21 12.20 6 53677 128 110535488
Growth retardation 21.04 12.20 14 53669 2568 110533048
Osteoporosis 21.03 12.20 91 53592 87061 110448555
Lymphadenopathy mediastinal 21.01 12.20 19 53664 5465 110530151
Cauda equina syndrome 20.99 12.20 13 53670 2109 110533507
Joint stiffness 20.89 12.20 76 53607 67167 110468449
Breast operation 20.85 12.20 8 53675 452 110535164
High-pitched crying 20.74 12.20 4 53679 13 110535603
Hepatic lesion 20.66 12.20 23 53660 8470 110527146
Mean cell haemoglobin increased 20.62 12.20 19 53664 5598 110530018
Metastases to bone marrow 20.61 12.20 10 53673 1004 110534612
Hepatic cyst 20.54 12.20 22 53661 7761 110527855
Retinal detachment 20.31 12.20 26 53657 11074 110524542
Spinal pain 20.23 12.20 34 53649 18481 110517135
Retroperitoneal fibrosis 20.12 12.20 9 53674 751 110534865
Loss of personal independence in daily activities 20.07 12.20 26 53657 149994 110385622
Insulin-like growth factor increased 20.05 12.20 13 53670 2283 110533333
Borrelia infection 19.96 12.20 7 53676 306 110535310
Benign lymph node neoplasm 19.54 12.20 4 53679 19 110535597
Autoimmune disorder 19.50 12.20 4 53679 65479 110470137
Polyneuropathy 19.47 12.20 46 53637 31966 110503650
Invasive lobular breast carcinoma 19.32 12.20 9 53674 825 110534791
Therapy non-responder 19.31 12.20 29 53654 157278 110378338
Haemorrhoids 19.29 12.20 49 53634 35623 110499993
Jaw operation 19.22 12.20 9 53674 835 110534781
Ovarian mass 19.11 12.20 8 53675 568 110535048
Metastases to uterus 18.91 12.20 5 53678 82 110535534
Gastrointestinal haemorrhage 18.91 12.20 32 53651 165486 110370130
Incorrect route of product administration 18.90 12.20 4 53679 64057 110471559
Mobility decreased 18.87 12.20 56 53627 237366 110298250
Menopause 18.87 12.20 13 53670 2525 110533091
Unresponsive to stimuli 18.79 12.20 4 53679 63786 110471830
Drug abuse 18.74 12.20 36 53647 177375 110358241
Breast haemorrhage 18.70 12.20 6 53677 199 110535417
Polymyositis 18.61 12.20 15 53668 3693 110531923
Meningioma 18.57 12.20 18 53665 5647 110529969
Blood oestrogen increased 18.55 12.20 6 53677 204 110535412
Mucosal inflammation 18.51 12.20 94 53589 96047 110439569
Superinfection 18.31 12.20 18 53665 5745 110529871
Grip strength decreased 18.27 12.20 8 53675 80166 110455450
Constipation 18.25 12.20 259 53424 357527 110178089
Exposed bone in jaw 18.25 12.20 15 53668 3796 110531820
Oroantral fistula 18.21 12.20 7 53676 398 110535218
Bladder irritation 18.21 12.20 7 53676 398 110535218
Drug intolerance 18.20 12.20 119 53564 406393 110129223
Vision blurred 18.15 12.20 116 53567 128906 110406710
Drug ineffective for unapproved indication 18.13 12.20 14 53669 102824 110432792
Tooth loss 18.13 12.20 21 53662 8075 110527541
Tibia fracture 18.06 12.20 19 53664 6566 110529050
Glomerulonephritis rapidly progressive 18.03 12.20 12 53671 2203 110533413
Full blood count abnormal 17.96 12.20 64 53619 55988 110479628
Neoplasm recurrence 17.86 12.20 17 53666 5215 110530401
Epiphyseal fracture 17.82 12.20 3 53680 3 110535613
Ebola disease 17.82 12.20 3 53680 3 110535613
Jaundice 17.60 12.20 66 53617 59170 110476446
Gingival swelling 17.59 12.20 17 53666 5313 110530303
Pneumonia 17.47 12.20 310 53373 876404 109659212
Burn oesophageal 17.40 12.20 7 53676 449 110535167
Anti-neutrophil cytoplasmic antibody positive vasculitis 17.36 12.20 17 53666 5400 110530216
Ill-defined disorder 17.30 12.20 31 53652 156822 110378794
Intermenstrual bleeding 17.25 12.20 19 53664 6915 110528701
Ocular discomfort 17.23 12.20 21 53662 8512 110527104
Pneumonia aspiration 17.15 12.20 9 53674 81224 110454392
Suicide attempt 17.09 12.20 15 53668 103379 110432237
Pelvic pain 17.05 12.20 29 53654 15913 110519703
Mastectomy 16.86 12.20 10 53673 1501 110534115
Antisynthetase syndrome 16.68 12.20 6 53677 283 110535333
Cardiac arrest 16.67 12.20 45 53638 196708 110338908
Pulmonary fibrosis 16.63 12.20 15 53668 102027 110433589
Osteoradionecrosis 16.39 12.20 5 53678 140 110535476
Hypoaesthesia teeth 16.37 12.20 4 53679 47 110535569
Spondylolisthesis 16.23 12.20 14 53669 3784 110531832
Autoimmune pancreatitis 16.17 12.20 8 53675 838 110534778
Postoperative wound complication 16.13 12.20 10 53673 1626 110533990
Hydrothorax 16.00 12.20 10 53673 1648 110533968
Transient acantholytic dermatosis 15.92 12.20 6 53677 323 110535293
Blood cholesterol increased 15.85 12.20 42 53641 184743 110350873
Abdominal discomfort 15.82 12.20 119 53564 393739 110141877
Sedation 15.81 12.20 7 53676 69676 110465940
Vertebral column mass 15.79 12.20 6 53677 330 110535286
White blood cell count abnormal 15.60 12.20 18 53665 6891 110528725
Toothache 15.58 12.20 35 53648 23540 110512076
Vertigo 15.39 12.20 83 53600 86787 110448829
Gene mutation 15.39 12.20 13 53670 3416 110532200
Actinomycosis 15.30 12.20 9 53674 1331 110534285
Endometrial hypertrophy 15.27 12.20 5 53678 177 110535439
Infection 15.23 12.20 108 53575 362092 110173524
Vitreous adhesions 15.22 12.20 4 53679 64 110535552
Injection site erythema 15.16 12.20 14 53669 94162 110441454
Rhabdomyosarcoma 15.08 12.20 5 53678 184 110535432
Sepsis 15.07 12.20 95 53588 327251 110208365
Hyperandrogenism 15.07 12.20 3 53680 12 110535604
Bile duct adenocarcinoma 15.07 12.20 3 53680 12 110535604
Poor peripheral circulation 15.02 12.20 14 53669 4183 110531433
Drug dependence 15.01 12.20 3 53680 50017 110485599
Lymphadenopathy 14.90 12.20 66 53617 63769 110471847
Pain in extremity 14.90 12.20 325 53358 486793 110048823
Cytomegalovirus infection 14.88 12.20 4 53679 54440 110481176
Peripheral swelling 14.87 12.20 125 53558 403909 110131707
Bronchitis 14.79 12.20 34 53649 156998 110378618
Intentional overdose 14.78 12.20 26 53657 132475 110403141
Blood pressure fluctuation 14.77 12.20 9 53674 74815 110460801
Subacute cutaneous lupus erythematosus 14.76 12.20 15 53668 4979 110530637
Cutaneous vasculitis 14.75 12.20 24 53659 12705 110522911
Dental caries 14.69 12.20 24 53659 12749 110522867
Metastases to thyroid 14.68 12.20 4 53679 74 110535542
Skin atrophy 14.65 12.20 17 53666 6547 110529069
Endometrial cancer 14.56 12.20 11 53672 2465 110533151
Squamous cell breast carcinoma 14.53 12.20 3 53680 15 110535601
Portal fibrosis 14.47 12.20 7 53676 698 110534918
Blood growth hormone increased 14.41 12.20 8 53675 1060 110534556
Retinopathy 14.38 12.20 14 53669 4415 110531201
Disease recurrence 14.30 12.20 63 53620 60721 110474895
Psoriasis 14.28 12.20 29 53654 139964 110395652
Multiple organ dysfunction syndrome 14.17 12.20 33 53650 151677 110383939
Sjogren's syndrome 14.02 12.20 7 53676 748 110534868
Follicular lymphoma 14.02 12.20 7 53676 748 110534868
Road traffic accident 13.97 12.20 19 53664 107379 110428237
Breast swelling 13.81 12.20 9 53674 1595 110534021
Axillary mass 13.79 12.20 7 53676 774 110534842
Lichen sclerosus 13.74 12.20 8 53675 1160 110534456
Body height decreased 13.74 12.20 21 53662 10542 110525074
Hair colour changes 13.68 12.20 14 53669 4687 110530929
Thrombosis 13.66 12.20 95 53588 108567 110427049
Portal vein thrombosis 13.66 12.20 17 53666 7041 110528575
Breast cancer in situ 13.54 12.20 8 53675 1193 110534423
Chronic inflammatory demyelinating polyradiculoneuropathy 13.46 12.20 10 53673 2185 110533431
Injection site reaction 13.46 12.20 14 53669 89056 110446560
Cardiotoxicity 13.39 12.20 27 53656 16854 110518762
Neuroectodermal neoplasm 13.31 12.20 3 53680 24 110535592
Dry eye 13.26 12.20 58 53625 55735 110479881
Visual acuity reduced 13.24 12.20 40 53643 32133 110503483
Uterine cancer 13.19 12.20 13 53670 4161 110531455
Pustule 13.15 12.20 12 53671 3492 110532124
BRCA2 gene mutation 13.11 12.20 4 53679 112 110535504
Bone marrow infiltration 13.09 12.20 7 53676 861 110534755
Electrocardiogram QT interval 13.08 12.20 5 53678 280 110535336
Hypercalcaemia 13.05 12.20 51 53632 46606 110489010
Metastases to thorax 12.99 12.20 5 53678 285 110535331
Chronic hepatitis 12.99 12.20 9 53674 1763 110533853
Delirium 12.91 12.20 29 53654 134996 110400620
Hip fracture 12.90 12.20 42 53641 35109 110500507
Burning sensation 12.85 12.20 67 53616 69145 110466471
Tumour marker abnormal 12.81 12.20 5 53678 296 110535320
Cataract 12.79 12.20 74 53609 79411 110456205
Neuralgia 12.77 12.20 52 53631 48426 110487190
Cutaneous sarcoidosis 12.77 12.20 6 53677 561 110535055
Hormone level abnormal 12.74 12.20 10 53673 2370 110533246
Nipple oedema 12.71 12.20 3 53680 30 110535586
Henoch-Schonlein purpura 12.71 12.20 12 53671 3645 110531971
Drug screen false positive 12.57 12.20 8 53675 1361 110534255
Hepatic steatosis 12.56 12.20 52 53631 48779 110486837
Sensitive skin 12.56 12.20 12 53671 3700 110531916
Depressed level of consciousness 12.55 12.20 22 53661 112256 110423360
Meibomian gland dysfunction 12.54 12.20 5 53678 313 110535303
Anaemia 12.54 12.20 351 53332 546735 109988881
Hospitalisation 12.52 12.20 32 53651 142461 110393155
Jaw disorder 12.48 12.20 14 53669 5198 110530418
Peripheral sensory neuropathy 12.43 12.20 26 53657 16654 110518962
Pain of skin 12.42 12.20 29 53654 20000 110515616
Vascular purpura 12.40 12.20 12 53671 3759 110531857
Drug reaction with eosinophilia and systemic symptoms 12.30 12.20 13 53670 82082 110453534
Dupuytren's contracture 12.29 12.20 3 53680 35 110535581
Rouleaux formation 12.29 12.20 3 53680 35 110535581
Metastases to eye 12.25 12.20 5 53678 333 110535283
Respiratory disorder 12.23 12.20 10 53673 71372 110464244
Antiphospholipid syndrome 12.22 12.20 10 53673 2513 110533103
Functional endoscopic sinus surgery 12.22 12.20 3 53680 36 110535580
Bacteriuria 12.21 12.20 8 53675 1430 110534186

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BG03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Aromatase inhibitors
FDA MoA N0000175080 Aromatase Inhibitors
FDA EPC N0000175563 Aromatase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50790 EC 1.14.14.14 (aromatase) inhibitor
CHEBI has role CHEBI:176497 geroprotector
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D047072 Aromatase Inhibitors
MeSH PA D065088 Steroid Synthesis Inhibitors

Related Drugs by ATC class:

L02BG Aromatase inhibitors 5 drugs
aminoglutethimideexemestaneformestaneletrozolevorozole

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hormone receptor positive malignant neoplasm of breast indication 417181009
Malignant tumor of ovary off-label use 363443007 DOID:2394
Hypercholesterolemia contraindication 13644009
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Aromatase Enzyme INHIBITOR IC50 6.22 WOMBAT-PK CHEMBL
Aromatase Enzyme IC50 5.41 CHEMBL

External reference:

IDSource
4020948 VUID
N0000148427 NUI
D00960 KEGG_DRUG
262485 RXNORM
C0290883 UMLSCUI
CHEBI:2704 CHEBI
CHEMBL1399 ChEMBL_ID
DB01217 DRUGBANK_ID
D000077384 MESH_DESCRIPTOR_UI
2187 PUBCHEM_CID
5137 IUPHAR_LIGAND_ID
7274 INN_ID
2Z07MYW1AZ UNII
173198 MMSL
4200 MMSL
5599 MMSL
d03873 MMSL
4020948 VANDF
005094 NDDF
108774000 SNOMEDCT_US
386910003 SNOMEDCT_US
2Z07MYW1AZ INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7536 TABLET, FILM COATED 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 16729-035 TABLET 1 mg ORAL ANDA 26 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 21695-990 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 23155-857 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 24979-725 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 42254-161 TABLET 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 42291-016 TABLET 1 mg ORAL ANDA 32 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 42291-085 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 43063-383 TABLET 1 mg ORAL ANDA 32 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 45865-909 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 50090-2453 TABLET 1 mg ORAL ANDA 26 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5002 TABLET 1 mg ORAL ANDA 31 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5002 TABLET 1 mg ORAL ANDA 31 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50268-075 TABLET 1 mg ORAL ANDA 31 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 51655-638 TABLET 1 mg ORAL ANDA 15 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 51991-620 TABLET 1 mg ORAL ANDA 32 sections
ARIMIDEX HUMAN PRESCRIPTION DRUG LABEL 1 54868-5000 TABLET 1 mg ORAL NDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 54868-6130 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole Human Prescription Drug Label 1 59651-236 TABLET, FILM COATED 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 60687-112 TABLET, COATED 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 60763-376 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 62033-0376 TABLET, COATED 1 mg ORAL Export only 17 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 62135-490 TABLET 1 mg ORAL ANDA 30 sections
ARIMIDEX HUMAN PRESCRIPTION DRUG LABEL 1 62559-670 TABLET 1 mg ORAL NDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 63187-080 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 63629-5269 TABLET 1 mg ORAL ANDA 26 sections
Anastrozole Human Prescription Drug Label 1 63850-0010 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 65841-743 TABLET, COATED 1 mg ORAL ANDA 1 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 66336-533 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 67877-171 TABLET 1 mg ORAL ANDA 26 sections